In an interview, synthetic biologist Peter Carr explains research on synthetic cells, their potential benefits and hazards, ...

Crinetics Pharmaceuticals leads as the cleanest buyout candidate at $3.79 billion; Cytokinetics' FDA-approved Myqorzo attracts Bristol Myers Squibb or Novartis but costs $10.86 billion. ARWR's ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

NEW DELHI-Aurobindo Pharma on March 17 said that the US Food and Drug Administration (USFDA) has classified one of its subsidiary units as “Official Action Indicated” following an inspection conducted ...

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year. 2025 was a slow year for IPOs, with ...

Public markets are beginning to reopen for biotech companies after several years of muted activity. But the strongest companies may still be more likely to sell themselves to Big Pharma rather than ...

If you’ve been tracking last week’s initial public offering of SpaceX, and the forthcoming IPOs of OpenAI and Anthropic, it’s a little like staring into the sun: everything else looks a little washed ...

Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track ...

June 7 (Reuters) - US biotech Incyte Pharma (INCY.O), opens new tab is nearing a deal ‌for up to $2 billion to buy blood disorder drug developer Star Therapeutics, ⁠the Financial Times reported on ...

The drumbeat of news regarding Asian pharma—and particularly China—continues to grow louder. At the American Society of Clinical Oncology (ASCO) meeting, Akeso took center stage with an ivonescimab ...